{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:28:58Z","timestamp":1782160138001,"version":"3.54.5"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Lipid metabolism disorders are recognized to be one of the most frequent complications of renal transplantation, while dyslipidemia and chronic kidney disease (CKD) are strong risk factors for arteriosclerotic cardiovascular disease (ASCVD). Proprotein convertase subtilisin\/kexin type 9 inhibitors (PCSK9i) are novel lipid-lowering drugs, the safety and efficacy of which are yet to be confirmed in transplanted patients. There have been several small-sample studies using PCSK9i in patients after heart transplantation, while fewer cases use PCSK9i after kidney transplantation. We report a case of a renal transplant recipient complicated with hepatitis B treated with PCSK9i, which achieved a remarkable lipid-lowering efficacy, and no significant adverse effects were found during the follow-up.<\/jats:p>","DOI":"10.3389\/fcvm.2022.937474","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T04:31:08Z","timestamp":1667795468000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["PCSK9 inhibitors in a renal transplant patient complicated with hepatitis B: A case report and literature review"],"prefix":"10.3389","volume":"9","author":[{"given":"Pinchao","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/14740338.2020.1732921","article-title":"Treatment of dyslipidemia in kidney transplantation.","volume":"19","author":"Ponticelli","year":"2020","journal-title":"Expert Opin Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/ndt\/gfz053","article-title":"Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies.","volume":"34","author":"Rangaswami","year":"2019","journal-title":"Nephrol Dial Transplant."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1178122X19827606","DOI":"10.1177\/1178122X19827606","article-title":"Effect of hepatitis B virus (HBV) infection on lipid profile in ghanaian patients.","volume":"10","author":"Quaye","year":"2019","journal-title":"Virology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trre.2004.03.001","article-title":"Cardiovascular disease in renal transplantation: management by statins.","volume":"18","author":"Fellstr\u00f6m","year":"2004","journal-title":"Transpl Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1161\/CIRCULATIONAHA.116.023687","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"B6","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1161\/CIRCULATIONAHA.116.023687","article-title":"Pleiotropic effects of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) inhibitors?","volume":"134","author":"Bittner","year":"2016","journal-title":"Circulation."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0210373","DOI":"10.1371\/journal.pone.0210373","article-title":"Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation.","volume":"14","author":"K\u00fchl","year":"2019","journal-title":"PLoS One."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/ndt\/gfz122","article-title":"Proprotein convertase subtilisin\/kexin type 9 in kidney disease.","volume":"34","author":"Schmit","year":"2019","journal-title":"Nephrol Dial Transplant."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the fourier trial.","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.rec.2019.08.002","article-title":"Treatment of hypercholesterolemia with PCSK9 inhibitors in heart transplant recipients. First experience in Spain.","volume":"72","author":"Groba-Marco","year":"2019","journal-title":"Rev Esp Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cardfail.2021.02.018","article-title":"PCSK9 inhibitors in heart transplant patients: safety, efficacy, and angiographic correlates.","volume":"27","author":"Sammour","year":"2021","journal-title":"J Card Fail."},{"key":"B14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jaccas.2019.09.026","article-title":"Use of PCSK9 inhibitors in solid organ transplantation recipients.","volume":"2","author":"Warden","year":"2020","journal-title":"JACC Case Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jacl.2019.01.011","article-title":"Management of dyslipidemia in adult solid organ transplant recipients.","volume":"13","author":"Warden","year":"2019","journal-title":"J Clin Lipidol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1161\/ATVBAHA.115.307030","article-title":"Low-density lipoprotein receptor-dependent and low-density lipoprotein receptor-independent mechanisms of Cyclosporin A-induced dyslipidemia.","volume":"36","author":"Kockx","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s43440-020-00090-6","article-title":"Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1.","volume":"72","author":"Sato","year":"2020","journal-title":"Pharmacol Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jacl.2019.06.010","article-title":"PCSK9 inhibition in patients with heart transplantation: a case series.","volume":"13","author":"Sandesara","year":"2019","journal-title":"J Clin Lipidol."},{"key":"B19","doi-asserted-by":"crossref","first-page":"104.e1","DOI":"10.1016\/j.cjca.2018.11.004","article-title":"Safety and efficacy of PCSK9 inhibitors after heart transplantation.","volume":"35","author":"Moayedi","year":"2019","journal-title":"Can J Cardiol."},{"key":"B20","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1097\/TP.0000000000002520","article-title":"Safety and efficacy of PCSK9 inhibitor treatment in heart transplant patients.","volume":"103","author":"Di Nora","year":"2019","journal-title":"Transplantation."},{"key":"B21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.7399\/fh.11138","article-title":"Pneumonia in a patient with kidney transplant treated with alirocumab and everolimus.","volume":"43","author":"Ordonez-Fernandez","year":"2019","journal-title":"Farm Hosp."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1177\/1060028013504077","article-title":"An observational study of ezetimibe in cardiac transplant recipients receiving calcineurin inhibitors.","volume":"47","author":"Makkar","year":"2013","journal-title":"Ann Pharmacother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jacl.2016.05.004","article-title":"Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: a case report.","volume":"10","author":"Nagashima","year":"2016","journal-title":"J Clin Lipidol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jacl.2021.05.003","article-title":"Early use of PCSK9 inhibitor therapy after heart transplantation from a hepatitis C virus positive donor.","volume":"15","author":"Fanous","year":"2021","journal-title":"J Clin Lipidol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.937474\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T04:31:16Z","timestamp":1667795476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.937474\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":24,"alternative-id":["10.3389\/fcvm.2022.937474"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.937474","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"article-number":"937474"}}